Replies to post #24313 on Mymetics Corp (MYMX)

[Work Harder]

Due to incorrect reporting, the Handelszeitung , the largest Swiss business newspaper, stopped working with Hässig. [8] Other journalists criticize Hässig's dubious methods and accuse him of inadequate reporting and pseudo-critical alarmism. [8] The Credit Suisse sued Haessig because of competitive harm and injured personality rights, including Bank Julius Baer and Falcon Private Bank have initiated legal action against him. [9] [10] [11]

Still a very legit rag

The Swiss Lukas Fierz is a neurologist, politician – and writer

https://www.karrierefuehrer.de/aerzte/lukas-fierz-interview.html

After graduating, I attended lectures on computer technology at the Swiss Federal Institute of Technology in Zurich in 1969

I was trained by a boss at the University Of Internmedical Hospital in Geneva.

[Work Harder]

Together with ImmunityBio (NASDAQ: IBRX) from Los Angeles, she is working on an oral Covid vaccine that produced cellular immunity and antibodies in a monkey experiment. A phase 1 study is now underway in which two vaccine doses are vaccinated one after the other, in all conceivable combinations of injected and swallowed.

That from the AhsokaXC post

John Brennan

CIA

Sandeep “Bobby” Reddy, M.D.

Los Alamos

https://immunitybio.com/about/

Drug: hAd5-SFusion + N-ETSD ( Oral capsule)

https://translate.google.com/translate?hl=en&sl=de&u=https://insideparadeplatz.ch/2021/04/15/covid-impfung-ohne-spritze-ein-offenes-rennen/&prev=search&pto=aue

Drop da bomb already Kempers

OMG, stop the anti science insanity

[Work Harder]

Wesley Clark

Since then we have progressed into a late-stage clinical company with more than 40 Phase I, II, or III clinical trials (company sponsored and investigator initiated)

https://immunitybio.com/about/

398 million fully diluted shares outstanding

https://immunitybio.com/immunitybio-begins-trading-today-on-nasdaq-as-large-cap-biotechnology-company/

[Work Harder]

Single-Dose COVID-19 Nasal Vaccine Limits Infection in Monkeys

Washington University School of Medicine in St. Louis

University of Oxford and pharmaceutical company AstraZeneca,

In work completed at NIAID’s Rocky Mountain Laboratories in Hamilton, Montana, scientists immunized six macaques with ChAd-SARS-CoV-2-S and six with an inactive control; the immunization was delivered into the nose.

ChAd-SARS-CoV-2-S is licensed in India to Bharat Biotech as BBV154. In the United States and Europe, Precision Virologics, Inc., holds the license for the investigational vaccine.

https://www.niaid.nih.gov/news-events/covid-19-nasal-vaccine

Reference:

https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00046-X

The underdog coronavirus vaccines that the world will need if front runners stumble

On the basis of such results, Diamond feels that his team has “a mission” to push its vaccines into human trials, to “see if they're going to be one of the last ones standing — even if they’re not the first ones out there”. His university has completed a deal to license the intranasal vaccine to a manufacturer, but Diamond hasn’t yet found anyone to advance his team’s livestock-virus vaccine. Pharmaceutical company Merck is developing its own vaccine based on the same virus, which is also the backbone of the Ebola vaccine that the firm had approved in the United States and the European Union last year.

And last month, Baylor College of Medicine in Houston, Texas, announced that it had nonexclusively licensed its protein-based COVID-19 vaccine candidate to an Indian manufacturer, Biological E in Hyderabad. The vaccine, which is estimated to cost around $2 per dose, could be used on its own or to boost the immune response elicited by other vaccines, says Baylor vaccine scientist Maria Elena Bottazzi, who is co-leading the effort to develop it. “While we wait for the Warp Speed vaccines to really show us the data, we need to start thinking about second-generation vaccines.”

https://www.nature.com/articles/d41586-020-02583-z

Vaccine Roundup: Merck Wipes Out (and More)

https://blogs.sciencemag.org/pipeline/archives/2021/01/25/vaccine-roundup-merck-wipes-out-and-more

STAT has some interesting statements from IAVI to the effect that the intramuscular administration of the VSV vaccine may not have been the correct route.

https://www.statnews.com/2021/01/25/in-a-major-setback-merck-to-stop-developing-its-two-covid-19-vaccines-and-focus-on-therapies/

Not Mymx here

Work will continue on at least one of the vaccines, which is being developed in partnership with the International AIDS Vaccine Initiative (IAVI), to see if using a different route of administration would improve how effective it is.

[Work Harder]

2021 Speakers

World Vaccine Congress Washington

May 4 - 6

Nicholas Kartsonis, Senior Vice President Of Clinical Research, Infectious Diseases And Vaccines, Merck

Roy Baynes, Senior Vice President And Head Global Clinical Development, Chief Medical Officer, Merck Research Laboratories

https://www.terrapinn.com/conference/world-vaccine-congress-washington/speakers.stm

World Vaccine & Immunotherapy Congress West Coast 2021

Nov 30 - Dec 2

SCIENTIFIC ADVISORY BOARD

https://www.terrapinn.com/conference/world-vaccine-immunotherapy-congress-west-coast/Scientific-Advisory-Board.stm

How Merck, a Vaccine Titan, Lost the Covid Race

In an interview in August, Dr. Nicholas Kartsonis, Merck’s senior vice president of clinical research for vaccines and infectious diseases, said the company’s position as leading vaccine maker gave it the luxury of time. “We are a much larger company. We are not as beholden to having to be first,” he said.

https://www.nytimes.com/2021/02/10/health/merck-covid-vaccine.html

Give me therapeutics when this stuff has been sitting in cold storage for how long now ?

Trust the science

UNBELIEVABLE

[Work Harder]

COVID-19 vaccines — minus the needle? Researchers working on capsules, nasal sprays

https://www.latimes.com/california/story/2021-04-16/covid-19-vaccines-minus-the-needle-researchers-working-on-capsules-nasal-sprays

ImmunityBio, based in El Segundo, is the only company to be simultaneously testing both injectable and oral versions of its vaccine, according to FasterCures data.

So no one in LA would know the difference

LOL

In February, the FDA approved the expansion of a Phase 1 clinical trial by ImmunityBio to include two other versions of its COVID-19 vaccine: a capsule that can be swallowed and a tablet that dissolves under the tongue. The company has been testing the injectable version of its vaccine for six months. The tests are being administered by Hoag Hospital Newport Beach and have expanded from 35 to 140 participants.

ImmunityBio’s chairman and chief executive, Dr. Patrick Soon-Shiong, also owns the Los Angeles Times.

LOL

[Work Harder]

What a loss to our community of patients, scientists and the world. Jose was an innovator and he will be sorely missed by all. Rest In Peace and prayers to his family. A sad day.

https://twitter.com/DrPatSoonShiong?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

Downfall of Jose Baselga Respected Cancer Researcher Due to Careless Disclosure Mistakes Verified Through Open Payments

https://www.policymed.com/2018/09/downfall-of-respected-cancer-researcher-due-to-careless-mistakes.html

Top Cancer Researcher Fails to Disclose Corporate Financial Ties in Major Research Journals

https://www.nytimes.com/2018/09/08/health/jose-baselga-cancer-memorial-sloan-kettering.html

[Work Harder]

Excited to be presenting at the Africa’s Vaccine Manufacturing For Health Security virtual conference at 9am PST.

https://twitter.com/DrPatSoonShiong?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor

https://africacdc.org/event/virtual-conference-expanding-africas-vaccine-manufacturing/

MilliporeSigma Helps Accelerate Global Access to Affordable Vaccines
Collaboration with Oxford University to develop cost-effective vaccine manufacturing processes, accelerate vaccine availability
Company also planning new vaccine manufacturing facility in Ghana to help country and region address health challenges

https://www.emdmillipore.com/US/en/20180411_152830

This partnership, as well as plans to develop a vaccine manufacturing facility in Ghana, further the company's commitment to improving global health by making vaccines more affordable and available.

https://www.thepharmaletter.com/in-brief/brief-milliporesigma-helps-accelerate-global-access-to-affordable-vaccines

Chapter 2: The next generation of COVID-19 vaccineshttps://t.co/ZWRN7Xvrdg

— Dr. Pat Soon-Shiong (@DrPatrick) February 13, 2021

https://www.latimes.com/science/081-yjln28o-123

Ghana to begin vaccine production

https://www.ghanaweb.com/GhanaHomePage/business/Ghana-to-begin-vaccine-production-610546

[Work Harder]

He is married to a violinist

& they live in Bern

He knows